Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared ...
In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's ...
Stocktwits on MSN
Nvidia’s expanding role in AI-driven drug discovery, clinical research could fuel growth, says Goldman Sachs
Goldman Sachs says rising demand for advanced computing power in specialized industries continues to strengthen Nvidia’s ...
Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ: RXRX), a leading tech-bio company decoding biology ...
2d
Goldman is betting Nvidia will get a boost from health care as industry builds out AI capabilities
Nvidia is looking to increase the adoption of AI by biotechnology companies, which could boost its shares, per Goldman Sachs.
Cathie Wood’s ARK Invest actively rotated out of large-cap technology, crypto-linked equities, and consumer internet names ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from ...
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.94, representing a -6.67% change from its previous ...
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ARK Invest sold $84M in Meta, Nvidia, AMD, and chip stocks on March 26, 2026. See why Cathie Wood trimmed big tech and what ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results